Novasep, a CDMO focused on complex small molecules and ADCs, completed the merger with PharmaZell, the German producer of highly resilient and specialty APIs. Financial terms were not disclosed. “We are very excited to partner with Novasep. The combined entity would serve our customers as a partner for complex molecules. Combining Novasep and PharmaZell, this new integrated approach would benefit our customers who would gain from the simplicity and efficiency of working with one company along the lifecycle of a drug. We look forward to bringing together our teams to deliver science and complex products to our customers and patients. We are committed to making this partnership a success," Sylke Hassel, PharmaZell CEO.